Maravai LifeSciences Holdings financials
$7.65+0.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $51.4M | $65.8M | $49.9M | $41.6M | $47.4M | $46.9M | $56.6M | $69.0M | $69.4M | $64.2M | $74.1M | $66.9M |
| Gross profit | $20.6M | $33.7M | $12.8M | $5.7M | $7.8M | $7.7M | $19.4M | $32.2M | $30.8M | $25.8M | $39.0M | $30.2M |
| Gross margin | 40.1% | 51.2% | 25.8% | 13.6% | 16.4% | 16.5% | 34.3% | 46.7% | 44.4% | 40.3% | 52.6% | 45.1% |
| Operating income | -$15.1M | -$2.2M | -$58.8M | -$41.0M | -$66.3M | -$49.2M | -$37.7M | -$165.6M | -$13.4M | -$18.9M | -$7.2M | -$15.4M |
| Net income | -$12.4M | -$3.7M | -$35.7M | -$25.6M | -$39.6M | -$29.9M | -$25.9M | -$97.1M | -$9.8M | -$12.1M | -$106.0M | -$6.5M |
| Net margin | −24.1% | −5.7% | −71.6% | −61.4% | −83.5% | −63.9% | −45.8% | −140.6% | −14.1% | −18.8% | −142.9% | −9.7% |
| Diluted EPS | $-0.08 | $-0.02 | $-0.25 | $-0.18 | $-0.27 | $-0.21 | $-0.18 | $-0.68 | $-0.07 | $-0.09 | $-0.80 | $-0.05 |
| EBITDA | -$3.3M | $12.1M | -$10.1M | -$20.5M | -$22.7M | -$24.0M | -$13.4M | $556.0K | -$1.0M | -$8.4M | -$4.0M | -$2.1M |
| Operating cash flow | $4.0M | $8.7M | -$22.8M | -$15.2M | -$10.3M | -$9.4M | -$14.6M | $13.1M | $17.4M | -$8.5M | $7.8M | $11.8M |
| Free cash flow | $3.6M | $4.2M | -$24.9M | -$18.1M | -$13.1M | -$13.9M | -$20.5M | $4.5M | $7.9M | -$14.1M | -$9.0M | -$4.0M |
| Diluted shares | 148.0M | 146.4M | 145.1M | 144.7M | 144.2M | 143.4M | 141.9M | 141.6M | 135.8M | 132.3M | 132.1M | 131.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $70.1M | $165.9M | $216.9M | $243.6M | $269.9M | $285.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $176.7M | $270.9M | $321.9M | $323.2M | $325.4M | $326.7M |
| Total assets | $603.7M | $713.2M | $770.6M | $849.2M | $897.0M | $959.8M |
| Total liabilities | $248.2M | $344.1M | $397.9M | $417.3M | $429.0M | $429.5M |
| Shareholders' equity | $355.6M | $369.1M | $372.7M | $431.9M | $468.0M | $530.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology